Distinct Alterations in the Composition of Mucosal Innate Lymphoid Cells in Newly Diagnosed and Established Crohns Disease and Ulcerative Colitis Show others and affiliations
2019 (English) In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 13, no 1, p. 67-78Article in journal (Refereed) Published
Abstract [en]
Background and Aims: Innate lymphoid cells [ILC] have been suggested to play a role in inflammatory bowel disease [IBD]. Here, we investigated the ILC compartment in intestinal biopsies and blood from distinct patient groups with Crohns disease [CD] and ulcerative colitis [UC], either newly diagnosed or with disease established for at least 1 year. This approach allowed us to simultaneously investigate temporal, disease-specific, and tissue-specific changes in ILC composition in IBD. Methods: ILC subset frequencies, phenotype, and transcription factor profile in blood and intestinal biopsies were investigated by multi-parameter flow cytometry analysis. Endoscopic disease severity was judged using the ulcerative colitis endoscopic index of severity and the simple endoscopic score for Crohns disease. Results: The frequency of NKp44(+)ILC3 was decreased in inflamed tissue, both in patients with CD and those with UC, already at the time of diagnosis, and correlated with disease severity. Simultaneously, the frequency of ILC1 was increased in patients with CD, whereas the frequency of ILC2 was increased in patients with UC. However, in patients with established UC or CD, both ILC1 and ILC2 were increased. In contrast to the ILC composition in inflamed tissue, ILC in non-inflamed tissue or blood were unchanged compared with non-IBD controls. Finally, in patients undergoing treatment with an anti-alpha(4)beta(7) antibody the frequencies of ILC in peripheral blood remained unchanged. Conclusions: We report both shared and distinct changes in ILC composition depending on diagnosis and disease duration. The alterations in ILC composition in IBD occur selectively at inflamed sites in the gut.
Place, publisher, year, edition, pages OXFORD UNIV PRESS , 2019. Vol. 13, no 1, p. 67-78
Keywords [en]
Innate lymphoid cells; inflammatory bowel disease; vedolizumab
National Category
Gastroenterology and Hepatology
Identifiers URN: urn:nbn:se:liu:diva-155019 DOI: 10.1093/ecco-jcc/jjy119 ISI: 000459355900009 PubMedID: 30496425 OAI: oai:DiVA.org:liu-155019 DiVA, id: diva2:1294816
Note Funding Agencies|Swedish Research Council [521-2013-2791]; Swedish Foundation for Strategic Research [ICA12-0023, FFL15-0120]; Swedish Society for Medical Research [4-140/2014]; Knut and Alice Wallenberg Foundation [4-1198/2016]; Torsten Soderberg Foundation [M196/13]; Karolinska Institutets Forskningsfonder [2014fobi42063]; Bengt Ihre-Fonden [2012-SLS 254491]
2019-03-082019-03-082025-02-11